GlassScriptPhysician profile
Ki Mun Chang
NPI 1649363656
$5,515.31
in general payments reported to CMS, 2019-2025
33 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $118 · 2021: $188 · 2022: $476 · 2023: $1,113 · 2024: $1,740 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,153 · Travel and Lodging: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,153.22 |
| Travel and Lodging | $258.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $834.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $702.98 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $645.05 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Novo Nordisk INC | $490.77 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $475.38 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.59 | 2019-2025 | Jardiance |
| Amgen INC. | $327.27 | 2020-2025 | Otezla, Repatha, Repatha |
| Medtronic, INC. | $292.15 | 2023 | Clydesdale Ptc Spinal System, Pivox Oblique Lateral Spinal System |
| Kowa Pharmaceuticals America, INC. | $185.30 | 2019-2024 | Livalo, Seglentis |
| Glaxosmithkline, LLC. | $184.71 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $124.87 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $100.48 | 2024-2025 | Voquezna |
| Abbott Laboratories | $97.95 | 2024-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $85.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $79.17 | 2019-2024 | Xarelto, Spravato |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $71.27 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $65.91 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.26 | 2024 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $44.95 | 2022-2024 | Quviviq |
| Antares Pharma, INC. | $44.56 | 2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $37.30 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.70 | 2022 | |
| Allergan, INC. | $28.01 | 2019 | |
| Shield Therapeutics INC | $27.52 | 2023-2024 | Accrufer |
| Daiichi Sankyo INC. | $25.64 | 2024 | Injectafer |
| Pulmonx Corporation | $23.78 | 2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Edwards Lifesciences Corporation | $19.48 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Alnylam Pharmaceuticals INC. | $18.96 | 2023 | Givlaari |
| Boston Scientific Corporation | $15.75 | 2024 | Watchman Flx |
| Assertio Therapeutics, INC. | $15.18 | 2019 | |
| Currax Pharmaceuticals LLC | $14.62 | 2024 | Contrave |
| Sanofi-Aventis U.S. LLC | $13.42 | 2019 | |
| Esperion Therapeutics, INC. | $13.11 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ki Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.